StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
JSLL.BO$492.55-1.87%
Fair $492.55+0.0%

JSLL.BO

Jeena Sikho Lifecare Limited

Healthcare / Medical Care FacilitiesBSE

$492.55

-11.70 (-1.87%)

Fairly Valued+0.0%Fair Value $492.55Fund rank 28/100 · Data gapFallback financials|
SA 49/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 20%

FCF escenarios

weak_data · normalized FCF $421.7M · quality 48.7/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 24/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

49/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · JSLL.BOLocal privado en este navegador · Jeena Sikho Lifecare Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$61.2B

P/E

28.8x

↑

EV/EBITDA

17.5x

↑

ROE

47.5%

↑

Gross Margin

88.6%

↑

Debt/Equity

0.27

↑
52-Week Range$493
$535$850

TradingView lightweight chart

JSLL.BO price, volumen y niveles de valoración

Último $614.90Periodo -14.2%
Fair value: $492.55

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+57.8%

FCF CAGR

—

FCF margin

27.4%

FCF / Net income

0.99x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $8.01B · net income $2.22B · FCF $2.19B

2023-FY → 2026-FY

Gross margin

88.6%-0.7% pts

Operating margin

37.7%+15.0% pts

Net margin

27.7%+11.1% pts

FCF margin

27.4%+37.7% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$8.01B$8.01B$4.69B$3.24B$2.04B
Net Income$2.22B$2.22B$799.4M$692.1M$337.4M
EBITDA$3.58B$3.58B$1.47B$990.9M$482.0M
EPS17.8117.816.425.572.74
Gross Margin88.6%88.6%88.4%90.4%89.3%
Operating Margin37.7%37.7%23.8%27.1%22.7%
Net Margin27.7%27.7%17.0%21.3%16.5%
Balance Sheet
Debt/Equity0.270.270.040.000.01
Cash Flow
Free Cash Flow$2.19B$2.19B$421.7M$211.5M$-210.3M
Returns
ROE47.5%47.5%29.3%36.0%26.8%
Valuation
P/E28.8228.82———
EV/EBITDA17.4517.45———
P/B13.1413.14———
Growth & Yield
Revenue Growth70.8%70.8%44.6%59.1%—
EPS Growth177.4%177.4%15.3%103.4%—
Dividend Yield0.2%0.2%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

34.9%

muy exigente

EPS terminal req.

$43.71

Spread vs growth

142.5%

5Y implied EPS CAGR

24.3%

exigente

EPS terminal req.

$52.88

Spread vs growth

153.1%

10Y implied EPS CAGR

16.9%

exigente

EPS terminal req.

$85.17

Spread vs growth

160.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total -14.0%

Total return

-14.0%

Start / end P/E

111.6x → 34.5x

EPS bridge

6.42 → 17.81

Residual

-122.5%

EPS growth+177.4%
Multiple rerating-69.1%
Dividend+0.2%
Residual / FX / buybacks / cross-term-122.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.